Call for regular and high-profile, late-breaker abstracts for ILC 2021
EASL is pleased to announce the second round of abstract submissions for ILC 2021. We are calling for companies, scientists, researchers, and investigators to submit regular and high-profile, late-breaker abstracts, 10–27 April…
A-TANGO – An EU-funded clinical Phase II study gives cirrhosis patients new hope
About EASL and the A-TANGO Consortium The A-TANGO Consortium, a five-year project, consists of 14 institutions across eight countries in Europe. It aims to perform Phase II clinical studies of an innovative…
Calling the global hepatology community to benefit now from early fees!
There is only one week left to take advantage of ILC 2021 early fees! The deadline is Monday, 22 March 23:59 CET. Don't wait for the last minute to save up to EUR…
EASL welcomes nurses, allied health professionals, and Young Investigators at ILC 2021
EASL’s ILC 2021 will be the 56th iteration of a flagship annual congress – a firmly rooted tradition that is set to be a sparkling, four-day virtual event taking place 23–26 June 2021. Over half a century has…
Become part of the next generation of EASL’s leadership!
Are you deeply engaged in hepatology and science and ready to get involved in EASL’s governance? EASL is now looking to fill the following positions: EASL Vice-Secretary Three Educational Committee Members Three Policy and Public Health…
On Rare Disease Day, we honour the many, the strong, the proud
EASL honours Rare Disease Day, taking place this Sunday, 28 February. An estimated 300 million people globally are affected by rare diseases – diseases of which 6,000 have been identified.
Global survey shows impact of COVID-19 response on hepatitis prevention care and treatment
In the wake of the COVID-19 pandemic, several liver associations recommended certain changes in hepatitis clinical care to mitigate transmission risks for severe acute respiratory syndrome coronavirus 2 (SARSCoV-2), the causative agent…